Navigation Links
Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity
Date:1/6/2011

PALO ALTO, Calif., Jan. 6, 2011 /PRNewswire/ -- Viveve, Inc., a development stage women's health company, announced today that it has received the European CE (Conformite Europeenne) mark for the use of its Viveve System for the non-surgical treatment of laxity of the vaginal introitus (opening), after childbirth, to improve female sexual function.

(Logo:  http://photos.prnewswire.com/prnh/20110106/SF25673LOGO)

"The CE mark is a key milestone in our commercialization strategy," said Kerry Pope, President and CEO of Viveve.  "We have heard from key opinion leaders in Europe and Canada about the Viveve procedure and the importance of its availability to their patients."

"I can say that worldwide, research and development to benefit women's sexual function have not been at the forefront of medical innovation," stated Dr. Michael Krychman, Gynecologist and Executive Director, The Southern California Center for Sexual Health and Survivorship, Newport Beach CA. "With the CE mark, Viveve can bring their procedure to my European colleagues whose patients I believe will benefit from this procedure."

"We'll immediately begin building our distribution network within the European Union as well as other countries that rely on the CE mark process, such as Canada and Australia," Pope continued.  "Our clinical advisors along with our own research tell us that the market opportunity for the Viveve procedure in developed countries is substantial and we're looking forward to establishing our presence in Europe."

There are three components to the Viveve System: the RF generator that has been optimized for use in an office setting; the hand piece that is specifically designed for the application; and the single-use disposable tip. The procedure is performed in the doctor's office by a trained OB/GYN, without the need for anesthesia, in approximately 30 minutes. In 2009, a "First in Women" Non-Significant Risk IRB approved study using the Viveve System was conducted in the United States. All women in the study reported an improved feeling of vaginal tightness during intercourse at 1, 3 and 6 months post treatment. In addition, of the women who had experienced a decrease in sexual satisfaction at least 1-year post vaginal delivery, all reported an improvement in sexual satisfaction at 1, 3 and 6 month intervals. This study was published in September 2010 by the Journal of Sexual Medicine and can be found on the company website at www.viveve.com.

About Viveve™

Viveve is a privately held women's sexual health company based in Palo Alto, California. The Viveve System is a medical device used for the non-surgical procedure of post-birth laxity of the vaginal introitus, a medically recognized quality of life condition.  It is currently not available for sale in the U.S.

The company's Series A financing was led by GBS Venture Partners and 5AM Ventures. For more information, visit www.viveve.com or contact Sherree Lucas at +1-650-321-3332 ext 213.


'/>"/>
SOURCE Viveve, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
2. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
3. HA&W Obtains Approximately $2 M in Credits and Cash Grants for Clients Through the Therapeutic Discovery Project Program
4. China Sky One Medical Obtains SFDA Approval for Ciclopirox Olamine Vaginal Suppositories
5. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
6. Par Obtains Exclusive Rights to Market and Distribute Generic Zetia(R) in the U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
9. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
10. Derma Sciences Obtains Exclusive Worldwide Rights to MEDIHONEY(R)
11. Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , January 16, 2017 According to a new ... Opportunity Analysis and Industry Forecast, 2014 - 2022," the global antioxidants market generated ... registering a CAGR of 6.42% during the forecast period. In the natural antioxidants ... volume in 2015. Continue Reading ... ...
(Date:1/16/2017)... TORONTO , Jan. 16, 2017  Today, Analytics ... cost-effective medical devices, announced its expansion into JLABS @ ... Johnson Innovation,s life science incubators. As a resident in ... of cardiovascular medical device development and commercialization expertise. ... a life science innovation center that provides a flexible ...
(Date:1/15/2017)... DUBLIN , January 16, 2017 ... produits innovants à base de collagène pour la régénération de ... au poste de directeur général avec effet immédiat. ... Bill est ... qui a occupé plusieurs postes de gestion générale et de ...
Breaking Medicine Technology:
(Date:1/16/2017)... , ... January 16, 2017 , ... San Francisco dentist, ... Element, the latest in 3-D scanning device which is capable of taking digital impressions ... advances in dentistry, such as CAD CAM restorations , in terms of speed, ...
(Date:1/16/2017)... ... 16, 2017 , ... NexTec Group has been selected as a member of ... their accomplishments in the field of midmarket financial software. , Members of the VAR ... Selection is not based on revenue and those firms chosen represent a wide range ...
(Date:1/15/2017)... Ohio (PRWEB) , ... January 15, 2017 , ... ... applications, Gensuite’s Community Outreach is a program that strives to better communities around ... each global locations’ community. It also provides the opportunity for team members to ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... Companies has achieved accreditation for its specialty care services. Albertsons Companies is ... in-house specialty care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... ... choice of best physicians in eight Bay Area counties for 2017. Almost 1,000 ... healthcare research company managing the award process. Results were announced the magazine’s ...
Breaking Medicine News(10 mins):